Trade Summary

6 days ago, Herrmann Ken, serving as Dir at Aktis Oncology, Inc. (AKTS), sold 4,856 shares at $24.56 per share, for a total transaction value of $119,274.04.

This sale represents a 100.00% decrease in Herrmann Ken's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, July 20, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, July 22, 2026 (accepted Jul 21, 8:50 PM ET), 2 days after the trade was made.

Aktis Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.